Diagnostic Application of Blood-based Biomarkers for Neurodegenerative Diseases

Dr Meenakshi Dhanawat, is currently working as Associate Professor in Amity Institute of Pharmacy, Amity University Haryana. She has a background in Pharmaceutical Sciences with a specialization in Medicinal Chemistry. She has done Masters from NIPER, Mohali and the project was based on Glycosylamino acids. Her PhD is from IIT-BHU, Varanasi and she worked on CNS drug delivery targeting 5HT1A/2A receptor. Apart from that she has a vast experience in the extraction of herbal drugs. Area of interest are Synthetic Chemistry, Heterocyclic Chemistry, Nanotechnology, Drug Delivery, Prodrug and Co-Drug Drug Design Complexation, Polymer Chemistry, and their application in drug delivery.She has 17 years of teaching and research experience. She has attended several national and international conferences in india and abroad the recipient of the travelship award in DDD section of AAPS-2010, National Biotechnology Conference, California, USA. She has been able to grab the international travel grant from DBT and DST for attending the International Conference at California, USA and Munich, Germany Respectively. She has also grabbed many other fellowships awards, which includes Rajiv Gandhi National Fellowship. She has Published more than 85 Research/Reviews along with Patent-06, Books 6, Book Chapter 22, Book Editor 02, Copyright 01.Dr. Niraj Kumar Singh, current working as assistant professor at GLA University, Mthura UP has more than 10 years of research and teaching experiences in the field of pharmacy. He has published more than 20 articles in reputed international and national SCI peer reviewed journals having good impact factor. During my M Pharm work, he evaluated the natural pytochemicals as novel anti-asthmatic agents. During doctoral work he was basically involved in the neuropharmacology and explored the novel target and therapeutic strategy for the management of Alzheimer’s disease (AD). His research involves pharmacological evaluation of natural flavonoid as alternative pharamacophore for prevention and treatment of dementia especially AD. Further, he evaluated and explored the cellular and molecular mechanisms involved in the neuroprotective potential of natural flavonoid. His research work provides the new scope for the researchers and scientist further to establish and evaluate the efficacy and therapeutic potential of natural flavonoid for management, treatment and prevention neurodegenerative disorders like AD. Mr. Bhushan has a background in Pharmaceutical Sciences with a specialization in Pharmacology. He has done Masters from GLA University, Mathura and the project was based on Neurological disorders. Apart from that he is having experience in many pharmaceutical instruments and extraction of herbal drugs. His area of interest is Neurological Disorders, Natural compounds, molecular pathways and Drug Delivery. He is currently working as Asst. Professor in Institute of Pharmaceutical Research, GLA University Uttar Pradesh. He has 2 years of teaching and research experience. He has attended several national and international conferences in India. He has done her M. Pharmacy project on the topic of “Pharmacological evaluation of silibinin against 3-NP induced Huntington’s disease in rodents”. He has more than 19 Publications in nations and international journal. His area of interest is role of Herbal constituents in brain related disorder.Arun Kumar Singh is an Assistant Professor in the Department of Pharmacy at University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran , India. He completed his M.Pharm in Pharmaceutics from Galgotias University, Greater Noida. His research interests include nano-formulation, blockchain, IoT, machine learning, artificial intelligence, big data analytics, cancer biology, and neuroscience. He has contributed to academic books and book chapters and has published review articles in the areas of pharmaceutical sciences and healthcare technology. His work focuses on interdisciplinary approaches integrating pharmaceutical research with emerging digital and computational technologies. Garima Malik has completed her B. Pharmacy from Vaish Institute of Pharmaceutical Education and Research, Rohtak, and an M.Pharmacy from Chandigarh College of Pharmacy, Landran. She has more than 3 years of experience as an Assistant Professor in the Department of Pharmaceutics. Currently, she is working as an Assistant Professor at M.M College of Pharmacy, Maharishi Markandeshwar University, Mullana, Ambala, India. Ms Garima had about 1.5 years of experience as an officer in the Quality control department at Zenacts Pharma Manimajra, Chandigarh. Her M.Pharmacy project focused on the topic of “Preparation and evaluation of Fusidic acid loaded transferosomes amalgamated with gel for the management of burn wound infection”. She has published more than 10 publications, including 1 Patent, and 5 book chapters. Her area of interest is nanotechnology, hydrogels, biomaterials, and their application in drug delivery.

• 1. The Role of Biomarkers in Neurological Disorder2. Understanding the Role of Serum Biomarkers in Neurological Disorders3. Serum Glial Fibrillary Acidic Protein: Insights into Blood Biomarkers for Neurological Disorders4. The Role of Neurofilaments as Biomarkers in Neurological Disease Diagnosis5. Advances in Alzheimer’s Diagnosis: The Role of CSF and Blood Biomarkers6. The Role of Alpha-Synuclein and other Blood Biomarkers in Parkinson’s Disease Progression7. Advances in Huntington’s Disease Diagnostics: The Role of Blood Biomarkers8. Unveiling Amyotrophic Lateral Sclerosis: The Role of Blood Biomarkers in Diagnosis and Management9. Advances in Frontotemporal Dementia Diagnostics: The Emerging Role of Blood-Based Biomarkers10. From Research to Reality: Translating Blood Biomarkers into Clinical Practice11. Plasma biomarkers for neurodegenerative disorders12. Fluid biomarkers for the diagnosis of neurodegenerative diseases13. Advances in AI-based biomarker discovery for neurodegenerative diseases.14. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Trials